Association of MMP2-1306C/T and TIMP2G-418C polymorphisms in retinal vein occlusion

Experimental Eye Research

Volumn 113, Issue , 2013, Pages 151-155

  Ortak, Huseyin ^a   Demir, Selim ^a   Ateş, Ömer ^a   Söǧüt, Erkan ^a   Alim, Sait ^b   Benli, Ismail ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b Tokat State Hospital   (Turkey)

Author keywords

Matrix metalloproteinase; Polymorphisms; Retinal vein occlusion

Indexed keywords

EDETIC ACID; GELATINASE A; GENOMIC DNA; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; AGED; ALLELE; ARTICLE; DISEASE CARRIER; DNA EXTRACTION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETINA VEIN OCCLUSION; RISK ASSESSMENT; RISK FACTOR;

MATRIX METALLOPROTEINASE; POLYMORPHISMS; RETINAL VEIN OCCLUSION;

BODY MASS INDEX; DIABETES MELLITUS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERTENSION; LIPIDS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; ODDS RATIO; OPHTHALMOSCOPY; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL VEIN OCCLUSION; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84880339742     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.06.009     Document Type: Article

References (35)

1. Arakawa S., Yasuda M., Nagata M., Ninomiya T., Hirakawa Y., et al. Nine-year incidence and risk factors for retinal vein occlusion in a general Japanese population: the Hisayama Study. Invest. Ophthalmol. Vis. Sci. 2011, 52:5905-5909.
2. Basalyga D.M., Simionescu D.T., Xiong W., Baxter B.T., Starcher B.C., Vyavahare N.R. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004, 110:3480-3487.
3. Benjamin M.M., Khalil R.A. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 2012, 103:209-279.
4. Bergmeier W., Burger P.C., Piffath C.L., Hoffmeister K.M., Hartwig J.H., et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of invitro-aged or -injured mouse platelets. Blood 2003, 102:4229-4235.
5. Brassart B., Randoux A., Hornebeck W., Emonard H. Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. Clin. Exp. Metastasis 1998, 16:489-500.
6. Das A., McGuire P.G., Eriqat C., Ober R.R., DeJuan E., et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest. Ophthalmol. Vis. Sci. 1999, 40:809-813.
7. De Clerck Y.A., Darville M.I., Eeckhout Y., Rousseau G.G. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 1994, 139:185-191.
8. De La Paz M.A., Itoh Y., Toth C.A., Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest. Ophthalmol. Vis. Sci. 1998, 39:1256-1260.
9. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl.1):S62-S69.
10. Falcinelli E., Guglielmini G., Torti M., Gresele P. Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation. J.Thromb. Haemost. 2005, 3:2526-2535.
11. Fernandez-Patron C., Martinez-Cuesta M.A., Salas E., Sawicki G., Wozniak M., et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb. Haemost. 1999, 82:1730-1735.
12. Harsfalvi J., Stassen J.M., Hoylaerts M.F., Van Houtte E., Sawyer R.T., et al. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood 1995, 85:705-711.
13. Hirano K., Sakamoto T., Uchida Y., Morishima Y., Masuyama K., et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur. Respir. J. 2001, 18:748-752.
14. Lambert V., Wielockx B., Munaut C., Galopin C., Jost M., et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 2003, 17:2290-2292.
15. Leoncini G., Bruzzese D., Signorello M.G., Armani U., Piana A., et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb. Haemost. 2007, 97:218-227.
16. Li Z., Li L., Zielke H.R., Cheng L., Xiao R., et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am. J. Pathol. 1996, 148:121-128.
17. Martinez A., Salas E., Radomski A., Radomski M.W. Matrix metalloproteinase-2 in platelet adhesion to fibrinogen: interactions with nitric oxide. Med. Sci. Monit. 2001, 7:646-651.
18. Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., Kingwell B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1479-1484.
19. Ortak H., Söǧüt E., Demir H., Ardagil A., Benli I., Sahin S. Predictive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion. Clin. Experiment. Ophthalmol. 2012, 40:743-748.
20. Pepper M.S., Montesano R. Proteolytic balance and capillary morphogenesis. Cell. Differ. Dev. 1990, 32:319-327.
21. Pocsai Z., Tóth Z., Paragh G., Széles G., Adány R. Rapid genotyping of paraoxonase 55 and 192 mutations by melting point analysis using real time PCR technology. Clin. Chim. Acta 2003, 332:31-36.
22. Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J.Biol. Chem. 2001, 276:7549-7558.
23. Rehak J., Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye Res. 2008, 33:111-131.
24. Rehak M., Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J.Thromb. Haemost. 2010, 8:1886-1894.
25. Rogers S., McIntosh R.L., Cheung N., Lim L., Wang J.J., et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010, 117:313-319.
26. Sawicki G., Salas E., Murat J., Miszta-Lane H., Radomski M.W. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997, 386:616-619.
27. Srivastava P., Lone T.A., Kapoor R., Mittal R.D. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in north India. Arch. Med. Res. 2012, 43:117-124.
28. Steen B., Sejersen S., Berglin L., Seregard S., Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 1998, 39:2194-2200.
29. Steinbrugger I., Haas A., Maier R., Renner W., Mayer M. Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion. Mol. Vis. 2009, 15:609-618.
30. Wang Y., Su Y., Xu Y., Pan S.H., Liu G.D. Genetic polymorphism c.1562C>T of the MMP-9 is associated with macroangiopathy in type 2 diabetes mellitus. Biochem. Biophys. Res. Commun. 2010, 391:113-117.
31. Wong T.Y., Scott I.U. Clinical practice. Retinal-vein occlusion. N.Engl. J. Med. 2010, 363:2135-2144.
32. Yu P.K., Tan P.E., Morgan W.H., Cringle S.J., McAllister I.L., Yu D.Y. Age-related changes in venous endothelial phenotype at human retinal artery-vein crossing points. Invest. Ophthalmol. Vis. Sci. 2012, 53:1108-1116.
33. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999, 99:1788-1794.
34. Zhang L.Y., Ren K.,W. Meta-analysis of MMP2 -1306T allele as a protective factor in digestive cancer. Arch. Med. Res. 2011, 42:239-243.
35. Zitka O., Kukacka J., Krizkova S., Huska D., Adam V., et al. Matrix metalloproteinases. Curr. Med. Chem. 2010, 17:3751-3768.